Printer Friendly

Toxicity of diabetes in pregnancy.

Diabetes is the most common medical complication of pregnancy, occurring in up to 7%-8% of all pregnancies. Gestational diabetes mellitus (GDM), in which the onset or recognition of glucose intolerance occurs in pregnancy, accounts for approximately 90% of diabetes cases. Although most represent true GDM (type 3), a significant number of cases are newly diagnosed type 2 diabetes. Distinguishing the two types is important because uncontrolled pregestational diabetes can cause all aspects of developmental toxicity (growth alteration, structural anomalies, functional / neurobehavioral deficits, and death), whereas true GDM does not cause structural anomalies because its onset is usually after organogenesis. However, both types have the potential to cause major toxicity in the mother and her offspring.

Suboptimal treatment of diabetes is indicated by the biomarker [HbA.sub.1c], a measure of the mean blood glucose concentration over the preceding 6-8 weeks. [HbA.sub.lc] results when glucose and hemoglobin A react (glycosylation) to form an irreversible compound. Values above normal (greater than 6%, mean blood glucose level greater than 126 mg/dL) are associated with significant maternal, embryonic, fetal, neonatal, and adolescent morbidity and mortality.

Other than serial blood glucose levels, an elevated [HbA.sub.lc] level is the most useful biomarker for predicting diabetes-induced developmental toxicity. Normal levels of [HbA.sub.lc] in nondiabetic patients indicate that even euglycemia and/or brief periods of hyperglycemia cause glycosylation of hemoglobin A and result in accumulation over time. In pregnancy, fetal risk increases directly with increasing [HbA.sub.lc] levels, but it has been thought that the risk does not exceed that in nondiabetic pregnancies until [HbA.sub.lc] concentrations exceed 7% (mean blood glucose level greater than 154 mg/dL).

Recent data challenge this belief. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study examined the effects of hyperglycemia less severe than that in diabetes in 23,316 women. Inclusion requirements were a fasting plasma glucose level of 105 mg/dL or less; after a standard 75-g oral glucose test given between 24 and 32 weeks, a 2-hour plasma glucose level of 200 mg/dL or less; and glucose levels below the predefined threshold at 34-37 weeks (N. Engl. J. Med. 2008;358: 1991-2002).

The primary outcomes were a birth weight above the 90th percentile, a primary cesarean section, neonatal hypoglycemia, and fetal hyperinsuline-mia; secondary outcomes were preterm birth, shoulder dystocia or a birth injury, the need for intensive neonatal care, hyperbilirubinemia, and preeclampsia.

For most primary outcomes, there was a clear dose-response relationship between increasing glucose levels and increasing frequency of the outcomes. The strongest associations were increased birth weight and increased fetal hyper-insulinemia. There were also significant positive associations with secondary outcomes, especially preeclampsia.

In a 2009 study, the records of 14,693 women, who had been screened and treated for GDM between 1988 and 2001 using only the National Diabetes Data Group (NDDG) criteria, were evaluated on the basis of Carpenter-Coustan (CC) criteria. For both criteria, two of the four threshold values following a 100-g, 3-hour glucose tolerance test need to be exceeded for a diagnosis of GDM. The thresholds for the CC and NDDG, respectively, were a fasting blood glucose of 95 mg/dL and 105 mg/dL, a 1-hour blood glucose of 180 mg/dL and 190 mg/dL, a 2-hour level of 155 mg/dL and 165 mg/dL, and a 3-hour level of 140 mg/dL and 145 mg/dL. The CC and NDDG criteria would have diagnosed GDM in 5.1% and 3.3%.

Compared with controls (women without GDM by either criterion), the 273 women with GDM based on CC, but not NDDG criteria, had significantly higher odds of cesarean delivery, operative vaginal delivery, macrosomia (above 4,500 g), and shoulder dystocia. The authors recommended using the CC method because of its increased sensitivity (Obstet. Gynecol. 2009;114:326-32).

Maternal morbidity associated with poorly controlled pregestational diabetes can worsen underlying metabolic disturbances. Retinopathy and nephropathy may worsen during pregnancy. Ketoacidosis, preeclampsia, infection, and preterm birth also are more common when glucose control is suboptimal. The severity of these complications may be increased if there is underlying vascular disease. Moreover, maternal vascular disease can result in fetal growth restriction. For patients with GDM, poor third-trimester glucose control is associated with increased risks for preeclampsia, traumatic birth, and cesarean section.

A significant risk of major structural anomalies is a concern with uncontrolled types 1 and 2 diabetes early in gestation. An [HbA.sub.lc] of 8.1% has been reported as the threshold at which the rate of birth defects begins to exceed the background incidence. The defects result from hyperglycemia occurring before the 7th week of gestation. They are caudal regression syndrome (including defects of the sacrum and lumbar vertebrae, distal spinal cord disruption with neurologic impairment, and lack of growth in the caudal region); spina bifida, hydrocephalus, and other CNS defects such as anencephalus; cardiac anomalies (ventricular and atrial septal defects and transposition of great vessels); anal/rectal atresia; renal malformations (agenesis, cystic kidney, and ureter duplex); situs inversus (transposition of viscera); and femoral hypoplasia-unusual facies syndrome. Ventricular septal defects are the most common anomaly, and the caudal regression syndrome is the most characteristic.

An [HbA.sub.lc] level near 10% is associated with a birth defect rate of 20%-25%, according to an ACOG Practice Bulletin published in 2005 (Obstet. Gynecol. 2005;105:675-85). This is evidence that the dose-response relationship required to establish a causal association exists between plasma glucose and structural anomalies. Other toxicities include embryo-fetal death (spontaneous abortions before 20 weeks, stillbirths in the third trimester); intrauterine bone resorption; and macrosomia (resulting from fetal hyperinsulinemia). If the fetus is macro-somic, birth trauma including asphyxia is an additional risk.

Hyperglycemia in the latter portion of pregnancy is associated with major neonatal toxicity: neonatal hypoglycemia (from hyperinsulinemia), hyperbilirubinemia, hypocalcemia, polycythemia (may involve thrombosis in the neonate), and respiratory distress syndrome (from inhibition of pulmonary maturation by fetal hyperinsulinemia). Exposure to hyperglycemia during pregnancy also is associated with significantly increased risks of diseases in the adolescent, including morbid obesity chronic hypertension, and diabetes.

Taken in sum, poorly controlled diabetes in pregnancy extracts a heavy toll on the mother and her offspring.

MR. BRIGGS is pharmacist clinical specialist, Perinatal Support Services, Miller Children's Hospital, Long Beach, Calif; clinical professor of pharmacy at the University of California, San Francisco; and adjunct professor of pharmacy at UCLA. He is also a fellow of the American College of Clinical Pharmacy.
COPYRIGHT 2009 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:DRUGS, PREGNANCY, AND LACTATION
Author:Briggs, Gerald G.
Publication:OB GYN News
Date:Dec 1, 2009
Words:1075
Previous Article:Oral antihyperglycemic agents and diabetes in pregnancy.
Next Article:Most antibacterial drugs not associated with birth defects.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters